Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2013-02-04

Clinical Trial Update: Safety Study of JTT-302 in Subjects With Low HDL-C Levels [Phase 2]

View source ↗

Summary

The document notes the completion of a Phase 2 safety study of JTT-302 in people with low HDL cholesterol.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • JTT-302

Snippet

Sponsor: Akros Pharma Inc. | Conditions: Dyslipidemia | Phase 2 | Status: COMPLETED